美国联邦贸易委员会联合纽约、加州、伊利诺伊、北卡、俄亥俄、宾州和弗吉尼亚州司法部长，请求联邦法院以蔑视法庭罪起诉前制药高管Martin Shkreli 1。根据指控，Shkreli在2022年生效的终身制药行业禁令期间多次违规，包括交易数十家制药公司的股票并在社交媒体直播中讨论行业事务 1。
Shkreli因一桩重大药价欺诈案而遭受此禁令 1。他曾将抗寄生虫药Daraprim的价格从每粒17.50美元提高至750美元，涨幅超过4000% 1。因该案件，Shkreli被判处7年监禁 1。参与此次起诉的七个州曾在2020年与FTC共同起诉Shkreli参与Daraprim的反竞争计划 1。
The Federal Trade Commission and seven state attorneys general have filed a motion requesting that a federal court hold Martin Shkreli in contempt of court for repeatedly violating a lifetime ban from the pharmaceutical industry that took effect in 2022 1. The former pharmaceutical executive, who was sentenced to seven years in prison for illegally raising the price of the antiparasitic drug Daraprim by more than 4,000 percent, allegedly engaged in multiple stock trades of dozens of pharmaceutical companies and discussed industry business matters during social media livestreams while under the ban 1.
Shkreli's price manipulation of Daraprim increased the drug's cost from $17.50 per pill to $750 1. The motion filed this week accuses him of systematically circumventing the restrictions imposed on him 1. The seven states joining the FTC in the action are New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia—the same jurisdictions that, along with the FTC, had previously sued Shkreli in 2020 for his involvement in anticompetitive schemes related to Daraprim 1.
评论
还没有评论，欢迎留下第一条。